The Benefits of Intravenous Vitamin C as an Alternative Cancer Treatment
Vitamin C interacts with iron and other metals to create hydrogen peroxide. In high concentrations, hydrogen peroxide damages the DNA and mitochondria of cancer cells, shuts down their energy supply, and kills them outright. And unlike virtually all conventional chemotherapy drugs that destroy cancer cells – It is selectively toxic. No matter how high the concentration, Vitamin C does not harm healthy cells.
Lab studies reveal that this therapy is effective against many types of cancer, including lung, brain, colon, breast, pancreatic, and ovarian. Animal studies show that when human cancers are grafted into animals, high-dose IV vitamin C decreases tumor size by 41 to 53 percent ‘in diverse cancer types known for both their aggressive growth and limited treatment options.’ Additionally, numerous patient case reports have been written up in medical journals.
Riordan Clinic Case Studies on the Effectiveness of Intravenous Vitamin C Treatments
In September 1995, shortly after diagnosis of a primary tumor in the left kidney of a 52-year-old white female, a nephrectomy was performed. Histology confirmed renal cell carcinoma. In September 1996, a chest x-ray film revealed 4 1- to 3-crn masses in her lungs. One month later there were 8 1- to 3-cm masses in her lungs (7 in right lung, 1 in left). No new medical, radiation, or surgical therapies were performed prior to her visit to our clinic in October 1996, when she began IVC therapy. Her initial dose was 15 g, which increased to 65 g after 2 weeks, two per week. She was also started on: N-acetyl cysteine, 500 mg 1 p.o., QC); beta-1,3- glucan (a macrophage stimulator), 2.5 mg 3 p.o. QD; fish oil (300 mg eicosatetraenoic acid, 200 mg docosahexaenoic acid), 1 p.o. T ID; vitamin C, 9 g p.o. QD; betacarotene, 25,000 ICJ. p.o. BID; L-threonine, 500 mg p.o. QD (for a deficiency revealed by laboratory testing of serum); Bacillus laterosporus, 280 mg, 2 p.o. QD for intestinal Candida albicans, inositol hexaniacinate complex (500 mg niacin, 100 mcg chromium) 2 p.o. QD, and a no-refinedsugar diet. She continued IAA treatments until June 1997 when another chest x-ray film revealed resolution of 7 of the 8 masses, and reduction in the size of the 8th. According to the medical imaging report, “The nodular infiltrates seen previously in the right lung and overlying the heart are no longer evident and the nodular infiltrate seen in left upper lung field has shown marked interval decrease in size and only vague suggestion of an approximately 1 cm density.” The patient discontinued IAA treatments in June 1997. She has continued on an oral nutritional support program since that time, and 4 years later was well with no evidence of progression2.
In December 1985, a mass occupying the lower pole of the right kidney was discovered in a 70-vear-old white male. Pathology of the mass after a radical nephrecton-ty confirmed renal cell carcinoma. In March 1986 the patient was seen in our clinic. He was started on IVC, 30 g twice per week. In April 1986, six weeks after the x-ray film and CT scan studies, the oncologist’s report stated, the patient returns feeling well. His exam is totally normal. His chest xray shows a dramatic improvement in pulmonary nodules compared to six weeks ago. The periaortic lymphadenopathy is completely resolved… either he has had a viral infection with pulmonary lesions with lymphadenopathy that has resolved or (2) he really did have recurrent kidney cancer which is responding to your vitamin C therapy.” The oncology report in July 1996 stated, “there is no evidence of progressive cancer. He looks well… chest x-ray today is totally normal. The pulmonary nodules are completely gone. There is no evidence of lung metastasis, liver metastasis or lymph node metastasis today, whatsoever.” In 1986 the patient received 30 g infusions twice-weekly for 7 months. The treatments were then reduced to once per week for 8 more months. For an additional 6 months he received weekly, 15 g IAA infusions. The patient continued well, and was seen periodically at our clinic until early 1997 when he died, cancer-free, at age 82, 12 years after diagnosis.
A 55 year old woman with stage-IIIC papillary adenocarcinoma of the ovary and an initial CA-125 of 999. underwent surgery followed by six cycles of chemotherapy (paclitaxel, carboplatin) combined with oral and parenteral ascorbate. Ascorbate infusion began at 15 grams twice weekly and increased to 60 twice weekly. Plasma ascorbate levels above 200 mg/dL were achieved during infusion. After six weeks, ascorbate treatment continued for year, after which patient reduced infusions to once every two Patient also supplemented with vitamin E, coenzyme 010, vitamin beta-carotene, and vitamin A. After over 40 months from initial diagnosis and remains on ascorbate infusions, the patient’s all CT and PET are negative for disease, and her CA-125 levels remain normal.